Allergan to commence phase III trials of Botox for depression

Allergan will be moving ahead with phase III trials to evaluate the performance of Botox as a means of treating major depressive disorder.

This decision was based on the encouraging performance of the therapy in a recent phase II study, which assessed the efficacy, safety and tolerability of a single administration of two different doses of Botox in adult females with depression over a duration of up to 24 weeks.

A 30-unit dose of Botox dose was associated with superior efficacy in terms of alleviating the signs of depression when compared to placebo, with both the 30-unit and 50-unit dose shown to be well-tolerated.

Given these promising results, the company has elected to move ahead with this development programme for Botox, which remains one of Allergan's most commercially important brands.

David Nicholson, chief research and development officer at Allergan, said: "Given our in-depth and extensive clinical trial experience in central nervous system conditions including depression, we plan to move forward and develop a phase III programme for a potential new treatment option for patients."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.